Search

Displaying results 481 - 490 of 9347 in total
  1. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart … The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin

  2. Drug

    Edaravone

    go.drugbank.com/drugs/DB12243
    ApprovedInvestigational

    [L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe. … However, the drug manufacturer, Mitsubishi Tanabe Pharma, withdrew the Marketing Authorization Application (MAA) for edaravone from the European market on May 24, 2019, in response to the request made

  3. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

  4. Drug

    Vitamin A

    go.drugbank.com/drugs/DB00162
    ApprovedInvestigationalNutraceuticalVet approved

    Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the … It is enriched in the liver, egg yolks, and the fat component of dairy products.

    Mixtures: TL-Fluorivite, RE FAC-xSynonyms: (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
  5. Drug

    Cepeginterferon alfa-2B

    go.drugbank.com/drugs/DB12814
    Investigational

    Cepeginterferon alfa-2B is under investigation in clinical trial NCT01889433 (An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic

  6. Drug

    Remtolumab

    go.drugbank.com/drugs/DB15128
    Investigational

    Remtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12

  7. Drug

    Nerofe

    go.drugbank.com/drugs/DB14786
    Investigational

    Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).

  8. Drug

    Potassium alum

    go.drugbank.com/drugs/DB09087
    ApprovedWithdrawn

    Potassium alum is considered by the FDA as a generally recognized as safe (GRAS) substance. … [L1070] It is an inorganic salt, also called potassium aluminum sulfate with a formula of AlK(SO4)2 that is predominantly produced in the dodecahydrate form (AlK(SO4)2 * 12H2O).

    Mixtures: Gingibraid W Epineph and Alum 1e, Gingibraid W Epineph and Alum 2e
  9. Drug

    SPVN20

    go.drugbank.com/drugs/DB33936
    Experimental

    SPVN20 is under investigation in clinical trial NCT07807111 (Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy).

  10. Drug

    Evalstotug

    go.drugbank.com/drugs/DB19410
    Investigational

    Evalstotug is under investigation in clinical trial NCT05271604 (A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck).

    Synonyms: Immunoglobulin G1 [de-448-lysine], anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal BA3071 γ1-chain), disulfide with human monoclonal BA3071 κ-chain, dimer, Immunoglobulin G1-kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], monoclonal antibody